RecruitingNot Applicable

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

United States224 participantsStarted 2024-03-15

Plain-language summary

The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Mentally capable of understanding and completing informed consent for the study. * Precipitants with a lab verified diagnosis of SARS-CoV-2 or clinician note/record that an appropriate rapid test for SARS-CoV-2 was positive. * To qualify for long COVID group participants will need to have new, persistent symptoms related to SARS-CoV-2 infection. iv. No one under the age of 18. Exclusion Criteria: * Subject is unable to provide informed consent. * Primary Investigator or Sub-Investigator determines the participant's ongoing medical complaints that began after 1 November 2019 are not related to SARS-COV-2 but another disease process.

What they're measuring

Develop algorithm to classify RNA sequences to identify long COVID

Timeframe: 30 days

Trial details

NCT IDNCT06311435

SponsorMaxWell Clinic, PLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-03-15

View on ClinicalTrials.gov More Long COVID trials